Evidence map›Paper›PMID 28794881›Full record

ReviewJournal of intensive care2017

Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.

Ashitha L Vijayan, Vanimaya, Shilpa Ravindran, R Saikant, S Lakshmi, R Kartik, Manoj G

Open access · goldAbstract readReview
In one paragraph

Review in Journal of intensive care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed, 9 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

200 citing papers in PubMed, 9 syntheses or guidelines pooled it, 466 citations in OpenAlex.

  1. Pooled it
  2. Procalcitonin and Diabetic Foot Ulcer Infections: A Meta-Analysis.Endocrinology, diabetes & metabolism · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

140 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ashitha L VijayanDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
VanimayaDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
Shilpa RavindranDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
R SaikantDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
S LakshmiDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
R KartikDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
Manoj GDiagnostic Products Division, Corporate R&D Centre, HLL Lifecare Limited, Akkulam, Sreekariyam (P.O), Trivandrum, Kerala India.
HLL Lifecare (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSepsis is a global healthcare problem, characterized by whole body inflammation in response to microbial infection, which leads to organ dysfunction. It is becoming a frequent complication in hospitalized patients. Early and differential diagnosis of sepsis is needed critically to avoid unnecessary usage of antimicrobial agents and for proper antibiotic treatments through the screening of biomarkers that sustains with diagnostic significance. MAIN BODY OF ABSTRACT: Current targeting conventional markers (C-reactive protein, white blood cell, tumour necrosis factor-α, interleukins, etc.) are non-specific for diagnosing sepsis. Procalcitonin (PCT), a member of the calcitonin super family could be a critical tool for the diagnosis of sepsis. But to distinguish between bacterial versus viral infections, procalcitonin alone may not be effective. Rapid elevation in the concentration of procalcitonin and other newly emerging biomarkers during an infection and its correlation with severity of illness makes it an ideal biomarker for bacterial infection. Beside this, the procalcitonin levels can be used for monitoring response to antimicrobial therapy, diagnosis of secondary inflammations, diagnosis of renal involvement in paediatric urinary tract infection, etc. The present article summarizes the relevance of procalcitonin in the diagnosis of sepsis and how it can be useful in determining the therapeutic approaches.

conclusionFurther studies are needed to better understand the application of PCT in the diagnosis of sepsis, differentiating between microbial and non-microbial infection cases and determining the therapeutic approaches for sepsis.

Indexed as

Antibiotic therapyDiagnostic markerProcalcitoninSepsis

Identifiers

PMID28794881
PMCPMC5543591
OpenAlexW2744780151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.